Alzheimer Disease/Dementia

US adults want to know if they have Alzheimer disease and early, when treatment may slow it down; they are even willing to risk participation in trials of new drugs. Read more.

Your daily dose of the clinical news you may have missed.

In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.

Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.

Your daily dose of the clinical news you may have missed.

Data on use of lecanemab in real world clinical settings will come from a neurologic case series review and a retrospective chart review of long-term use, both in early AD.

In a small study of adults genetically predisposed to early-onset dementia, anti-amyloid treatment to remove plaque reduced risk of developing symptoms by 50%.

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Analysis of data from the donanemab TRAILBLAZER development program underscores the essential role of patient selection and treatment monitoring.

Axsome Therapeutics reported that the FDA feedback supports the company's regulatory package for a sNDA for the dextromethorphan/bupropion combination.

The proprietary combination of 2 neurostimulation modalities deployed simultaneously may enhance efficacy while reducing treatment time by 70%, the company said.

Phospho-tau serine-262 and serine-356 were identified as biomarkers for early Alzheimer disease detection in a new study published in Nature Medicine.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Dr Turner reviews the profile of the individual who is most likely to benefit from lecanemab therapy.

Georgetown University memory disorders expert R Scott Turner, PhD, MD, reviews the science behind approval of lecanemab for monthly maintenance dosing of lecanemab.

Once every four weeks maintenance dosing of lecanemab may be easier for patients and care partners to continue treatment.

The revolutionary medications are the first new treatments for Alzheimer disease to be approved in more than 20 years and the first-ever disease-modifying drugs.

Your daily dose of the clinical news you may have missed.

Levels of acetyl-L-carnitine and free carnitine correlated significantly with disease severity, particularly in women with moderate and severe Alzheimer dementia.

Vesper Bio anticipates completing enrollment and dosing by mid-2025 in the Phase 1B/2A trial for VES001.

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

Weekly SC injection of lecanemab is expected to maintain clinical and biomarker benefits reached during the IV initiation phase. The PDUFA date is Aug 31, 2025.

Blarcamesine significantly slowed progression of both cognitive and functional decline, with treatment initiated earlier in disease process more effective than that initiated later.

The study will assess the safety, tolerability, and pharmacokinetics of PMN310 in individuals with mild cognitive impairment or early-stage AD.

Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.